55
/
2
Min Read
Synthetic biology startup StrainX Bioworks has raised USD 13 million in a funding round co-led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dhoka Ventures and WTF (India) Delhi Angels.
The Bengaluru-based company said the funds will be used to expand its research and development capabilities, scale fermentation infrastructure and hire more scientific and engineering talent. It also plans to accelerate its global commercialisation efforts.
Founded in 2023 by IIT Delhi alumni Akshay Mittal and Alok Malviya, StrainX Bioworks focuses on precision fermentation technology. The company develops alternative proteins, enzymes and bioengineered metabolites for applications in the food, healthcare and agriculture sectors.
Over the past two years, it has been operating in stealth mode while building capabilities in strain engineering, fermentation processes, product development and industrial scale-up.
The startup aims to engineer biological systems that can produce high-value ingredients in controlled environments, reducing dependence on traditional plant and animal-based sources. It has demonstrated fermentation at a scale of 10,000 litres and is now working to expand production further. The company is preparing for commercialisation in India as well as in overseas markets, including the US.
Synthetic biology involves modifying microorganisms to produce compounds typically sourced from natural processes. These microbes are grown in industrial fermentation systems to manufacture proteins and ingredients. While widely used in pharmaceuticals, such technologies are increasingly being explored in food and consumer products as production costs decline.
This article was originally
published by the 
